Dana-Farber’s Breast Oncology Center shared on X:
“Hot off the Press!
Trastuzumab deruxtecan in HER2-positive advanced Breast Cancer with or without Brain Metastases practice changing results from a phase 3b/4 trial.”
Dana-Farber’s Breast Oncology Center shared on X:
“Hot off the Press!
Trastuzumab deruxtecan in HER2-positive advanced Breast Cancer with or without Brain Metastases practice changing results from a phase 3b/4 trial.”